Prospective evaluation of comprehensive geriatric assessments in multidisciplinary bladder cancer care and implications for personalized vulnerability phenotyping

By sjmartinez • May 3, 2025

Cavanaugh D, Holt SK, Dwyer E, Petersen E, Gore JL, Schade GR, Grivas P, Hsieh AC, Lee JK, Montgomery B, Schweizer MT, Yezefski T, Yu EY, Chen JJ, Liao JJ, Weg E, Zeng J, Jannat S, Berry DL, Master VA, Garcia JM, Reed MJ, Bentov I, Wright JL, Psutka SP. Prospective evaluation of comprehensive geriatric assessments in multidisciplinary bladder cancer care and implications for personalized vulnerability phenotyping. Urol Oncol. 2025 May 1:S1078-1439(25)00123-1. doi: 10.1016/j.urolonc.2025.03.025. Epub ahead of print. PMID: 40316478.

Tags: Hematology/Oncology, Publications

Related Posts

Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy

Nikitas J, Smith CP, Armstrong WR, Murthy V, Grogan T, Clark K, Moore J, Roberts M, Farolfi A, Reiter RE, Rettig MB, Shen J, Valle[...]

Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study

Dummer R, Guo J, Luke JJ, Carlino MS, Schadendorf D, Khattak MA, Hauschild A, Ascierto PA, Chen Y, Shin SJ, Rutkowski P, Luo Z, Chen[...]

NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial

Macarulla T, Cid RP, Womack MS, Gracian AC, Zervoudakis A, Hatoum H, Chung V, Patel A, Paulson AS, Pant S, O'Reilly EM, Hubner RA, Van[...]